Navigation

Macular oedema (retinal vein occlusion) - ranibizumab [ID328]

Ranibizumab for the treatment of macular oedema caused by retinal vein occlusion (RVO)

Status: History
Expected date of issue: TBC
Process: STA
Notes:

Scoped within Batch 11

Topic area:
  • Eye
 

NICE project team

Executive Lead: Andrew Dillon
Technical Lead: Christian Griffiths
Communications manager: Shalu Kanal
Project manager: Lori Farrar
Top


 

Provisional schedule

Closing date for invited submissions / evidence submission: 10 May 2011
1st appraisal committee meeting: 11 August 2011
2nd appraisal committee meeting 10 January 2012
3rd appraisal committee meeting: 13 February 2013
Top


 

Consultees and commentators

Consultees Commentators (no right to submit or appeal)

Manufacturers/sponsors

  • Novartis Pharmaceuticals (ranibizumab)

Patient/carer groups

  • Macular Disease Society
  • Royal National Institute of Blind People (RNIB)

Professional groups

  • Royal College of Nursing
  • Royal College of Ophthalmologists
  • Royal College of Physicians

Others

  • Department of Health
  • Welsh Assembly Government
  • Wiltshire PCT
  • Wirral PCT

General

  • British National Formulary
  • Commissioning Support Appraisals Service
  • Department of Health, Social Services and Public Safety for Northern Ireland
  • NHS Quality Improvement Scotland

Comparator manufacturers

  • Allergan (dexamethasone implant)
  • Roche Products (bevacizumab)

Relevant research groups

  • None

Evidence Review Group

  • BMJ Group
  • National Institute for Health Research  Health Technology Assessment Programme

Associated Guideline Groups

  • None

Associated public health groups

  • None

Top


 

Project history

Date Update
07 January 2013 Following the cancellation of the Appraisal Committee meeting on Thursday 11 October 2012, the Appraisal Committee meeting will now take place on Wednesday 13 February 2013.
3 April 2012

On 10 January, the Appraisal Committee met to consider comments received on the consultation document issued for the appraisal of ranibizumab for the treatment of macular oedema caused by retinal vein occlusion.

Following Committee’s consideration, and in line with section 3.5.49 (page 41) of the Guide to the Single Technology Appraisals Process, the Institute has asked for additional work to be commissioned by the NICE Decision Support Unit (DSU) related to the consideration of bevacizumab as a comparator in the appraisal of ranibizumab for the treatment of macular oedema caused by retinal vein occlusion. We anticipate that the Appraisal Committee will meet again towards the Autumn of 2012 to consider the DSU report.

12 October 2012 Due to the pending outcome of the on-going NICE Rapid review of TA237, ranibizumab for the treatment of diabetic macular oedema.  The discussion of Ranibizumab for the treatment of macular oedema caused by retinal vein occlusion (RVO) at the Appraisal Committee meeting on Thursday 11 October was cancelled.
Top


 

Key documents

This page was last updated: 02 July 2013

Accessibility | Cymraeg | Freedom of information | Vision Impaired | Contact Us | Glossary | Data protection | Copyright | Disclaimer | Terms and conditions

Copyright 2014 National Institute for Health and Care Excellence. All rights reserved.

Selected, reliable information for health and social care in one place

Accessibility | Cymraeg | Freedom of information | Vision Impaired | Contact Us | Glossary | Data protection | Copyright | Disclaimer | Terms and conditions

Copyright 2014 National Institute for Health and Care Excellence. All rights reserved.